A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies
This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies (chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), anaplastic large cell lymphoma, transformed mycosis fungoides (MF), or Sezary Syndrome). Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Keywordslymphoid malignancies, mycosis fungoides, relapsed, refractory, anaplastic large cell lymphoma
Principal InvestigatorNam H Dang, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.